Loading...
•
Mar 30, 2024
Haemonetics Q4 2024 Earnings Report
Haemonetics' Q4 2024 financial performance was strong, driven by revenue growth and margin expansion.
Key Takeaways
Haemonetics reported strong fourth quarter and fiscal year 2024 results, with revenue increasing by 13% to $343 million. The company advanced its market leadership through strategic investments and acquisitions, contributing to revenue growth and margin expansion.
Revenue increased by 13% to $343 million in the fourth quarter of fiscal 2024.
Organic revenue growth was 10% for the fourth quarter of fiscal 2024.
Adjusted earnings per diluted share increased by 16.9% to $0.90 in the fourth quarter of fiscal 2024.
The company is on track to deliver increased value to customers and shareholders.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company issued its fiscal 2025 GAAP total revenue and organic revenue growth guidance in its updated revenue reporting format.
Positive Outlook
- Total Company Reported Revenue Growth: 5-8%
- Hospital Revenue Growth: 27-32%
- Adjusted Operating Margin: 23-24%
- Adjusted earnings per diluted share: $4.45 - $4.75
- Free cash flow: $130M - $180M
Challenges Ahead
- Plasma Revenue Growth: (3-6)%
- Blood Center Revenue Growth: (5-8)%
- Currency Impact on Total Company Revenue: (0-1)%
- Organic revenue growth: 0-3%
- Currency impact on Blood Center Revenue: (0-1)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income